Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan^® Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study

References

• World Health Organization. Cardiovascular diseases (CVDs) Fact sheet. Available from: https://www.who.int/en/newsroom/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed March 14, 2023.
   Google Scholar
• Johnson ML, Pietz K, Battleman DS, et al. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care. 2004;10(12):926–932.
   PubMed Web of Science ®Google Scholar
• Lim S, Shin H, Song JH, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998–2007. Diabetes Care. 2011;34(6):1323–1328. doi:10.2337/dc10-2109
   PubMed Web of Science ®Google Scholar
• Stamler J, Wentworth D, Neaton D. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med. 1986;80:33–39. doi:10.1016/0002-9343(86)90158-0
   PubMed Web of Science ®Google Scholar
• Castelli P, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986;80:23–32.
   PubMed Web of Science ®Google Scholar
• Satoh M, Ohkubo T, Asayama K, et al. Evidence for Cardiovascular Prevention From Observational Cohorts in Japan (EPOCH-Japan) Research Group*. Combined effect of blood pressure and total cholesterol levels on long-term risks of subtypes of cardiovascular death: evidence for Cardiovascular Prevention from Observational Cohorts in Japan. Hypertension. 2015;65(3):517–524. doi:10.1161/HYPERTENSIONAHA.114.04639
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421. doi:10.1161/circ.106.25.3143
   PubMed Web of Science ®Google Scholar
• Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Int Med. 1971;74:1–12. doi:10.7326/0003-4819-74-1-1
   PubMed Web of Science ®Google Scholar
• Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens. 2002;11:489–496. doi:10.1097/00041552-200209000-00003
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497. doi:10.1001/jama.285.19.2486
   PubMed Web of Science ®Google Scholar
• Spannella F, Giulietti F, Di Pentima C, et al. Prevalence and control of dyslipidemia in patients referred for high blood pressure: the disregarded “Double-Trouble” lipid profile in overweight/obese. Adv Ther. 2019;36(6):1426–1437. doi:10.1007/s12325-019-00941-6
   PubMed Web of Science ®Google Scholar
• Petrella RJ, Merikle E. A retrospective analysis of the prevalence and treatment of hypertension and dyslipidemia in southwestern Ontario, Canada. Clin Ther. 2008;30(6):1145–1154. doi:10.1016/j.clinthera.2008.06.004
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719. doi:10.1016/j.amjmed.2006.08.033
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357. doi:10.1097/01.hjh.0000431740.32696.cc
   PubMed Web of Science ®Google Scholar
• Choi JM, Lee SH, Jang YJ, Kang M, Choi JH. Medication adherence and clinical outcome of fixed-dose combination vs. free combination of angiotensin receptor blocker and statin. Circ J. 2021;85(5):595–603. doi:10.1253/circj.CJ-20-0966
   PubMed Web of Science ®Google Scholar
• Dresser GK, Nelson SA, Mahon JL, et al. Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2). J Hypertens. 2013;31(8):1702–1713. doi:10.1097/HJH.0b013e3283619d6a
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Bacquer D, et al.; EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636–648. doi:10.1177/2047487315569401
   PubMed Web of Science ®Google Scholar
• Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini study). J Clin Hypertens. 2005;7(5):264–273. doi:10.1111/j.1524-6175.2005.04533.x
   Google Scholar
• Flack JM, Victor R, Watson K, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008;83(1):35–45. doi:10.4065/83.1.35
   PubMed Web of Science ®Google Scholar
• Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation. 2005;111(19):2518–2524. doi:10.1161/01.CIR.0000165070.46111.9F
   PubMed Web of Science ®Google Scholar
• Ihm SH, Shin J, Park CG, et al. Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito®) in Korean adults with hypertension and hypercholesterolemia. Drug Des Devel Ther. 2019;13:633–645. doi:10.2147/DDDT.S191973
   PubMed Web of Science ®Google Scholar
• Jang JY, Lee SH, Kim BS, et al. Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients [Published correction appears in Korean Circ J. 2015;45(4):349]. Korean Circ J. 2015;45(3):225–233. doi:10.4070/kcj.2015.45.3.225
   PubMed Web of Science ®Google Scholar
• Kim SH, Jo SH, Lee SC, et al. Blood pressure and cholesterol-lowering efficacy of a fixed-dose combination with irbesartan and atorvastatin in patients with hypertension and hypercholesterolemia: a randomized, double-blind, factorial, multicenter Phase III study. Clin Ther. 2016;38(10):2171–2184. doi:10.1016/j.clinthera.2016.09.005
   PubMed Web of Science ®Google Scholar
• Cho KI, Kim BH, Park YH, et al. Efficacy and safety of a fixed-dose combination of candesartan and rosuvastatin on blood pressure and cholesterol in patients with hypertension and hypercholesterolemia: a multicenter, randomized, double-blind, parallel phase III clinical study. Clin Ther. 2019;41(8):1508–1521. doi:10.1016/j.clinthera.2019.05.007
   PubMed Web of Science ®Google Scholar
• Park JS, Shin JH, Hong TJ, et al. Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: oLmesartan rosuvaSTAtin from Daewoong). Drug Des Devel Ther. 2016;10:2599–2609. doi:10.2147/DDDT.S112873
   PubMed Web of Science ®Google Scholar
• Oh GC, Han JK, Han KH, et al. Efficacy and safety of fixed-dose combination therapy with telmisartan and rosuvastatin in Korean patients with hypertension and dyslipidemia: TELSTA-YU (TELmisartanrosuvaSTAtin from YUhan), a multicenter, randomized, 4-arm, double-blind, placebo-controlled, phase III study. Clin Ther. 2018;40(5):676–691. doi:10.1016/j.clinthera.2018.03.010
   PubMed Web of Science ®Google Scholar
• Potier L, Roussel R, Elbez Y, et al. REACH Registry Investigators*. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart. 2017;103(17):1339–1346. doi:10.1136/heartjnl-2016-310705
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–207. doi:10.1016/S0140-6736(07)60108-1
   PubMed Web of Science ®Google Scholar
• Lee S-H. Update on familial hypercholesterolemia: diagnosis, cardiovascular risk, and novel therapeutics. Endocrinol Metab. 2017;32(1):36–40. doi:10.3803/EnM.2017.32.1.36
   Google Scholar
• Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229–243. doi:10.1161/CIRCRESAHA.116.308537
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187. doi:10.1097/HJH.0b013e3281fc975a
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375–2414. doi:10.1093/eurheartj/ehm316
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Leiter LA, Kallend D. A review of the efficacy of rosuvastatin in patients with type 2 diabetes. Int J Clin Pract Suppl. 2004;143:30–40. doi:10.1111/j.1368-504X.2004.00390.x
   Google Scholar
• Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. J Clin Hypertens. 2011;13(9):677–686. doi:10.1111/j.1751-7176.2011.00518.x
   PubMed Web of Science ®Google Scholar
• Korean guidelines for the management of dyslipidemia IV. Available from: https://www.lipid.or.kr/file/guidlines.pdf. Accessed March 14, 2023.
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–1252. doi:10.1161/01.HYP.0000107251.49515.c2
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520. doi:10.1001/jama.2013.284427
   PubMed Web of Science ®Google Scholar
• Leggio M, Lombardi M, Caldarone E, et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. Hypertens Res. 2017;40:947–963. doi:10.1038/hr.2017.75
   PubMed Web of Science ®Google Scholar
• Chopra I, Kamal KM, Candrilli SD, et al. Association between obesity and therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia. Postgrad Med. 2014;126(1):66–77. doi:10.3810/pgm.2014.01.2726
   PubMed Web of Science ®Google Scholar